A Study for Japanese Participants With Rheumatoid Arthritis (RA)

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and tolerability of multiple doses of LY2127399 (tabalumab) in Japanese participants with RA. The study consists of a 20-week treatment period. All participants will be followed for up to 12 weeks after the last study drug administration.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Have given written informed consent

• Women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation

• Diagnosis of RA

• Active RA

• Current, regular use of Methotrexate, at a stable dose

• Body weight between 40 and 105 kilograms (kg), inclusive

Exclusion Criteria:

• Use of excluded medications (reviewed by study doctor)

• Have medical findings which, in the opinion of the study doctor, put participant at an unacceptable risk for participation in the study

• Have had recent or ongoing infection which, in the opinion of the study doctor put participant at an unacceptable risk for participation

• Evidence of tuberculosis

• Have systemic inflammatory condition other than RA